CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today ...
VoiceThread Recording Submission Deadline (for those accepted for Virtual and In-person Posters): Jan. 26, 2026 at 5 p.m. Upon abstract acceptance, all posters must be uploaded and recorded on ...
The regional agency asked for the research to be undertaken aas the prospect of local projects have become a hot button issue.
High dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments at completion of 16-week induction period Interim data presented for patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback